Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610310 · ClinicalTrials.gov registry record · Phase 1
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01610310 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 55 participants.
The verdict
NCT01610310, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers to support the development of the autoinjector.
Interventions
- DEVICE BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)
- DEVICE BIIB017 (peginterferon beta-1a) Autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610310
The ClinicalTrials.gov registry entry for NCT01610310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) is the first listed.
NCT01610310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01610310 about?
NCT01610310 is a clinical study titled "Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers". The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers to support the development of the autoinjector.
What is the current status of trial NCT01610310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01610310?
The interventions under investigation include: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) (DEVICE), BIIB017 (peginterferon beta-1a) Autoinjector (DEVICE).
Who is sponsoring clinical trial NCT01610310?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.